ObjectiveTo investigate the efficacy and safety of CT-guided 125I particle implantation combined with chemotherapy in the treatment of advanced non-small cell lung carcinoma (NSCLC). MethodsA total of 96 patients with advanced NSCLC were selected as research objects and divided into observation group (n=39) and control group (n=57) according to the treatment methods. Patients in the control group received chemotherapy alone, while patients in the observation group received CT-guided 125I particle implantation combined with chemotherapy. The short-term efficacy and quality of life improvement, serum tumor marker levels before and after treatment, and the occurrence of adverse reactions (hemoptysis, pneumothorax, pleural effusion, bone marrow suppression, fever) during treatment were compared between the two groups. ResultsThe objective response rate, disease control rate and improvement rate of quality of life in the observation group were higher than those in the control group (all P＜0.05). After two cycles of treatment, the levels of squamous cell carcinoma antigen, serum carcinoembryonic antigen and cyto-keratin 19 fragment antigen 21-1 in the two groups were significantly lower than those before treatment, and the observation group yielded lower levels than the control group (all P＜0.05). No significant difference was found in the total incidence of adverse reactions between the two groups during treatment. (P＞0.05). ConclusionCT-guided 125I particle implantation combined with chemotherapy has significant short-term efficacy in the treatment of advanced NSCLC, which can effectively control the disease progression and improve patients′ quality of life, and has high safety.

无